Global Large Volume Wearable Injectors demand is anticipated to be valued at US$ 2,800.0 Million in 2022, forecast to grow at a CAGR of 8.9% to be valued at US$ 7,142.3 Million from 2022 to 2032. Growth is attributed to the shift of healthcare delivery toward home care.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2022) | US$ 2,800.0 Million |
| Anticipated Forecast Value (2032) | US$ 7,142.3 Million |
| Projected Growth Rate (2022 to 2032) | 8.9% CAGR |
Large Volume Injectors are used to administer a relatively large volume of medication in a short duration. They are commonly used for the rapid administration of medication in emergency cases for achieving peak drug concentration in blood plasma. Large-volume injectors are used to administer biological drug formulations, particularly those containing monoclonal antibodies because the biological formulation is viscous at high concentrations.
Therefore, a large volume is ideal for depot administrations and infrequent dosing. Large-volume injectors also decrease the dosing frequency which eliminates the dosing errors in medical facilities. Large-volume injectors are also used for regular dosing of incremental biological therapy in chronic disease indications. They also provide product differentiation through increased efficacy, safety, convenience, and tolerability.
Factors such as the advantages of wearable injectors in the administration of various drugs are expected to boost the growth of the Large Volume Wearable Injectors market in the near future.
On the other hand, the preference for alternative drug delivery modes is one of the major factors that is expected to hamper the growth of the Large Volume Wearable Injectors Market over the analysis period.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Large Volume Injectors reduce the injection workflow, are safer to use, and facilitate self-administration. Infusion site hypersensitivity reactions are the major issues for biological formulations. Reactions include pain, and swelling and may lead to fever, nausea, and headache.
To mitigate the risk of hypersensitivity reactions, such formulations are administered by slow infusion for several hours. These factors are expected to accelerate the growth of the Large Volume Wearable Injectors Market during the forecast period.
Factors such as the shift of healthcare delivery toward homecare due to COVID-19, advantages of wearable injectors in the administration of various drugs, the rising prevalence of chronic diseases (such as cancer, diabetes, and CVD), favorable reimbursement scenario in major markets, and technological advancements in injector devices are also expected to flourish the growth of the Large Volume Wearable Injectors over the analysis period.
The ability of large-volume injectors enables ambulatory drug delivery with increased safety driving the growth of the large-volume injectors market. In certain care pathways, patients need to be present for infusion on a regular basis to receive drug therapy for the extended treatment period.
These are because in most cases health care supervision is required for administrations of infusions. In such cases, large volume injectors increase the ability for patients to self-administration reduce the burden and increase patient compliance. Rising demand due to improved safety and efficacy drives the burgeoning growth of the large-volume injectors market.
A growing focus on the use of biologics and mAbs to treat diseases such as rheumatoid arthritis, cardiovascular disease, and cancer will provide significant growth opportunities for wearable injectors, as these drugs need to be administered via the parenteral route (intravenous, subcutaneous, or intramuscular delivery). All these factors are expected to offer lucrative opportunities for market growth in the near future.
Large-volume injectors administer 3ml or greater and may not frequently administer. They are little evidence-based data with appropriate use, potential efficacy, and side effects which is one of the major factors that is expected to hinder the growth of the large volume injectors during the forecast period.
The preference for alternative drug delivery modes, high costs, and a poor reimbursement structure in developing countries are some other factors that are anticipated to impede the growth of the large volume wearable injectors market in the forthcoming years.
Principal Consultant
In terms of regional platforms, North America holds the largest market share in the Large Volume Wearable Injectors market. The region is expected to surge to over 35.6% share from 2022 to 2032.
North America is expected to fuel the Large Volume Wearable Injectors market, attributed to the increased acceptance by the end-user population, and high penetration.
According to Future Market Insights, Europe is expected to hold lucrative growth opportunities for Large Volume Wearable Injectors and is expected to reach a significant share of 33.1% in 2022. Europe is expected to witness significant market growth, owing to rising awareness of the Large Volume Injectors Market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
According to Future Market Insights, Asia-Pacific is expected to grow with lucrative growth opportunities for Large Volume Wearable Injectors and is expected to reach a market share of 25.6% in 2022.
Asia-Pacific region accounts for a significant share of the Large Volume Wearable Injectors Market, attributed to continuous advancements in medical wearable technologies, which are boosting the prospects of the regional market, and is propelled increasingly by the growing burden of chronic diseases.
According to Future Market Insights, the Middle East & Africa are expected to provide significant growth opportunities for Large Volume Wearable Injectors Market and are expected to reach a share of 12.3% in 2022.
The developing Large Volume Wearable Injectors market in the Middle East & Africa is expected to aid in the flourishing market during the forecast period, owing to rapid industrialization in the developing countries of the region.
There are many prominent market players in the Large Volume Wearable Injectors Market such as Ypsomed Holding AG, Gerresheimer AG (Sensile Medical), West Pharmaceutical Services Inc., Unilife Corporation, SteadyMed Therapeutics, Inc., Enable Injections, Medgizmo, West Pharmaceutical Services, Inc., Terumo Corporation, and Sorrel Medical, among others, that are working hand-in-hand to provide the best-in-class Large Volume Wearable Injectors for enhancing the global Large Volume Wearable Injectors arena.
However, there are many global start-ups in the Large Volume Wearable Injectors Market, that are stepping forward in matching the requirements of the Large Volume Wearable Injectors domain.
Some of the key participants present in the global Large Volume Wearable Injectors market include Elcam Medical, Debiotech S.A, Becton, Dickinson and Company, Johnson & Johnson Services, Inc., F. Hoffmann-La Roche Ltd., Amgen, Inc., Insulet Corporation, CeQur SA, Medtronic Plc, Tandem Diabetes Care, Inc., and PerkinElmer Inc., among others.
Attributed to the presence of such high number of participants, the market is highly competitive. While global players such as Elcam Medical, Debiotech S.A, Becton, Dickinson and Company, Johnson & Johnson Services, Inc., F. and Hoffmann-La Roche Ltd. account for a considerable market size, several regional level players are also operating across key growth regions, particularly in North America.
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 8.9% from 2022 to 2032 |
| Market Value in 2022 | US$ 2,800.0 Million |
| Market Value in 2032 | US$ 7,142.3 Million |
| Base Year for Estimation | 2021 |
| Historical Data | 2016 to 2021 |
| Forecast Period | 2022 to 2032 |
| Quantitative Units | Revenue in USD Million, Volume in Kilotons, and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled | Elcam Medical, Debiotech S.A, Becton, Dickinson and Company, Johnson & Johnson Services, Inc., F. Hoffmann-La Roche Ltd., Amgen, Inc., Insulet Corporation, CeQur SA, Medtronic Plc, Tandem Diabetes Care, Inc., and PerkinElmer Inc., among others. |
| Customization | Available Upon Request |
FMI projects the global Large Volume Wearable Injectors market to expand at an 8.9% value CAGR by 2032
North America is expected to be the most opportunistic Large Volume Wearable Injectors market, expanding at a 35.6% market share
Elcam Medical, Debiotech S.A, Becton, Dickinson, and Company, Johnson & Johnson Services, Inc., and F. Hoffmann-La Roche Ltd. are some prominent Large Volume Wearable Injectors players
1. Executive Summary | Large Volume Wearable Injectors Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Product Life Cycle Analysis
3.5. Investment Feasibility Matrix
3.6. PESTLE and Porter’s Analysis
3.7. Regulatory Landscape
3.7.1. By Key Regions
3.7.2. By Key Countries
3.8. Regional Parent Market Outlook
4. Global Market Analysis 2016 to 2021 and Forecast, 2022 to 2032
4.1. Historical Market Size Value (US$ Million) Analysis, 2016 to 2021
4.2. Current and Future Market Size Value (US$ Million) Projections, 2022 to 2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute Opportunity Analysis
5. Global Market Analysis 2016 to 2021 and Forecast 2022 to 2032, By End User
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By End User, 2016 to 2021
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2022 to 2032
5.3.1. Hospitals
5.3.2. Clinics
5.3.3. Ambulatory Surgical Centers
5.3.4. Research Institutes
5.4. Y-o-Y Growth Trend Analysis By End User, 2016 to 2021
5.5. Absolute Opportunity Analysis By End User, 2022 to 2032
6. Global Market Analysis 2016 to 2021 and Forecast 2022 to 2032, By Region
6.1. Introduction
6.2. Historical Market Size Value (US$ Million) Analysis By Region, 2016 to 2021
6.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2022 to 2032
6.3.1. North America
6.3.2. Latin America
6.3.3. Europe
6.3.4. Asia Pacific
6.3.5. Middle East and Africa
6.4. Market Attractiveness Analysis By Region
7. North America Market Analysis 2016 to 2021 and Forecast 2022 to 2032, By Country
7.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2016 to 2021
7.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
7.2.1. By Country
7.2.1.1. United States of America
7.2.1.2. Canada
7.2.2. By End User
7.3. Market Attractiveness Analysis
7.3.1. By Country
7.3.2. By End User
7.4. Key Takeaways
8. Latin America Market Analysis 2016 to 2021 and Forecast 2022 to 2032, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2016 to 2021
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
8.2.1. By Country
8.2.1.1. Brazil
8.2.1.2. Mexico
8.2.1.3. Rest of Latin America
8.2.2. By End User
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By End User
8.4. Key Takeaways
9. Europe Market Analysis 2016 to 2021 and Forecast 2022 to 2032, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2016 to 2021
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
9.2.1. By Country
9.2.1.1. Germany
9.2.1.2. United Kingdom
9.2.1.3. France
9.2.1.4. Spain
9.2.1.5. Italy
9.2.1.6. Russia
9.2.1.7. Rest of Europe
9.2.2. By End User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By End User
9.4. Key Takeaways
10. Asia Pacific Market Analysis 2016 to 2021 and Forecast 2022 to 2032, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2016 to 2021
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
10.2.1. By Country
10.2.1.1. China
10.2.1.2. Japan
10.2.1.3. India
10.2.1.4. South Korea
10.2.1.5. Australia
10.2.1.6. Rest of Asia-Pacific
10.2.2. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By End User
10.4. Key Takeaways
11. Middle East and Africa Market Analysis 2016 to 2021 and Forecast 2022 to 2032, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2016 to 2021
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
11.2.1. By Country
11.2.1.1. South Africa
11.2.1.2. Saudi Arabia
11.2.1.3. UAE
11.2.1.4. Israel
11.2.1.5. Rest of Middle East and Africa
11.2.2. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By End User
11.4. Key Takeaways
12. Key Countries Market Analysis
12.1. United States of America
12.1.1. Pricing Analysis
12.1.2. Market Share Analysis, 2021
12.1.2.1. By End User
12.2. Canada
12.2.1. Pricing Analysis
12.2.2. Market Share Analysis, 2021
12.2.2.1. By End User
12.3. Brazil
12.3.1. Pricing Analysis
12.3.2. Market Share Analysis, 2021
12.3.2.1. By End User
12.4. Mexico
12.4.1. Pricing Analysis
12.4.2. Market Share Analysis, 2021
12.4.2.1. By End User
12.5. Germany
12.5.1. Pricing Analysis
12.5.2. Market Share Analysis, 2021
12.5.2.1. By End User
12.6. United Kingdom
12.6.1. Pricing Analysis
12.6.2. Market Share Analysis, 2021
12.6.2.1. By End User
12.7. France
12.7.1. Pricing Analysis
12.7.2. Market Share Analysis, 2021
12.7.2.1. By End User
12.8. Spain
12.8.1. Pricing Analysis
12.8.2. Market Share Analysis, 2021
12.8.2.1. By End User
12.9. Italy
12.9.1. Pricing Analysis
12.9.2. Market Share Analysis, 2021
12.9.2.1. By End User
12.10. Russia
12.10.1. Pricing Analysis
12.10.2. Market Share Analysis, 2021
12.10.2.1. By End User
12.11. China
12.11.1. Pricing Analysis
12.11.2. Market Share Analysis, 2021
12.11.2.1. By End User
12.12. Japan
12.12.1. Pricing Analysis
12.12.2. Market Share Analysis, 2021
12.12.2.1. By End User
12.13. India
12.13.1. Pricing Analysis
12.13.2. Market Share Analysis, 2021
12.13.2.1. By End User
12.14. South Korea
12.14.1. Pricing Analysis
12.14.2. Market Share Analysis, 2021
12.14.2.1. By End User
12.15. Australia
12.15.1. Pricing Analysis
12.15.2. Market Share Analysis, 2021
12.15.2.1. By End User
12.16. South Africa
12.16.1. Pricing Analysis
12.16.2. Market Share Analysis, 2021
12.16.2.1. By End User
12.17. Saudi Arabia
12.17.1. Pricing Analysis
12.17.2. Market Share Analysis, 2021
12.17.2.1. By End User
12.18. UAE
12.18.1. Pricing Analysis
12.18.2. Market Share Analysis, 2021
12.18.2.1. By End User
12.19. Israel
12.19.1. Pricing Analysis
12.19.2. Market Share Analysis, 2021
12.19.2.1. By End User
13. Market Structure Analysis
13.1. Competition Dashboard
13.2. Competition Benchmarking
13.3. Market Share Analysis of Top Players
13.3.1. By Regional
13.3.2. By End User
14. Competition Analysis
14.1. Competition Deep Dive
14.1.1. Becton, Dickinson, and Company
14.1.1.1. Overview
14.1.1.2. Product Portfolio
14.1.1.3. Profitability by Market Segments
14.1.1.4. Sales Footprint
14.1.1.5. Strategy Overview
14.1.1.5.1. Marketing Strategy
14.1.2. PerkinElmer, Inc.,
14.1.2.1. Overview
14.1.2.2. Product Portfolio
14.1.2.3. Profitability by Market Segments
14.1.2.4. Sales Footprint
14.1.2.5. Strategy Overview
14.1.2.5.1. Marketing Strategy
14.1.3. Medgizmo
14.1.3.1. Overview
14.1.3.2. Product Portfolio
14.1.3.3. Profitability by Market Segments
14.1.3.4. Sales Footprint
14.1.3.5. Strategy Overview
14.1.3.5.1. Marketing Strategy
14.1.4. West Pharmaceutical Services
14.1.4.1. Overview
14.1.4.2. Product Portfolio
14.1.4.3. Profitability by Market Segments
14.1.4.4. Sales Footprint
14.1.4.5. Strategy Overview
14.1.4.5.1. Marketing Strategy
14.1.5. Unilife Pharmachem Private Limited
14.1.5.1. Overview
14.1.5.2. Product Portfolio
14.1.5.3. Profitability by Market Segments
14.1.5.4. Sales Footprint
14.1.5.5. Strategy Overview
14.1.5.5.1. Marketing Strategy
14.1.6. SteadyMed Ltd.
14.1.6.1. Overview
14.1.6.2. Product Portfolio
14.1.6.3. Profitability by Market Segments
14.1.6.4. Sales Footprint
14.1.6.5. Strategy Overview
14.1.6.5.1. Marketing Strategy
14.1.7. Roche Holding AG
14.1.7.1. Overview
14.1.7.2. Product Portfolio
14.1.7.3. Profitability by Market Segments
14.1.7.4. Sales Footprint
14.1.7.5. Strategy Overview
14.1.7.5.1. Marketing Strategy
14.1.8. CeQur Corporation
14.1.8.1. Overview
14.1.8.2. Product Portfolio
14.1.8.3. Profitability by Market Segments
14.1.8.4. Sales Footprint
14.1.8.5. Strategy Overview
14.1.8.5.1. Marketing Strategy
14.1.9. Scpharmaceuticals Inc
14.1.9.1. Overview
14.1.9.2. Product Portfolio
14.1.9.3. Profitability by Market Segments
14.1.9.4. Sales Footprint
14.1.9.5. Strategy Overview
14.1.9.5.1. Marketing Strategy
14.1.10. Sensile Medical AG
14.1.10.1. Overview
14.1.10.2. Product Portfolio
14.1.10.3. Profitability by Market Segments
14.1.10.4. Sales Footprint
14.1.10.5. Strategy Overview
14.1.10.5.1. Marketing Strategy
15. Assumptions & Acronyms Used
16. Research Methodology
Explore Healthcare Insights
View Reports
Large Volume Wearable Injectors Market
